ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 0739 • ACR Convergence 2021

    Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)

    Uta Kiltz1, Eerik Ahomaa2, Björn Buehring1, Xenofon Baraliakos1, David Kiefer1, Jaclyn-Dalisay Leicht1 and Jürgen Braun1, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2St. Franziskus-Hospital, Department of Orthopedic Surgery, Cologne, Germany

    Background/Purpose: Functioning of axSpA patients (pat.) is influenced by many factors, but how contextual factors influence functioning isn’t well studied. According to the International Classification…
  • Abstract Number: 0925 • ACR Convergence 2021

    Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs

    Philip Mease1, Robert McLean2, Taylor Blachley2, Maya Marchese2, Laura Anatale-Tardiff3, Christopher Saffore4, Danny Quach5, Ana Biljan6 and Alexis Ogdie7, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2CorEvitas, LLC, Waltham, MA, 3CorEvitas, Waltham, MA, 4AbbVie, North Chicago, IL, 5AbbVie Inc., North Chicago, IL, 6Abbvie Inc., Chicago, IL, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Although Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity (LDA) is a common treatment target for disease control when managing AS, real-world research…
  • Abstract Number: 1344 • ACR Convergence 2021

    Impact of Achieving Minimal Disease Activity on Patient-Reported Outcome Measures and Disease Activity Among Patients with Psoriatic Arthritis Treated with Biologic and Targeted Synthetic DMARDs

    Alexis Ogdie1, Robert McLean2, Maya Marchese2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Kevin Douglas5, Danny Quach5 and Philip Mease6, 1University of Pennsylvania, Philadelphia, PA, 2CorEvitas, LLC, Waltham, MA, 3CorEvitas, Waltham, MA, 4AbbVie, North Chicago, IL, 5AbbVie Inc., North Chicago, IL, 6Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA

    Background/Purpose: Minimal disease activity (MDA) is a common goal for disease control when managing PsA. The aim of this study was to assess the association…
  • Abstract Number: 0402 • ACR Convergence 2021

    What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?

    Alain Lescoat1, Susan Murphy2, Yen Chen3, Nadia Vann1, David Cella4 and Dinesh Khanna3, 1Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 2University of Michigan, Grosse Ile, MI, 3University of Michigan, Ann Arbor, MI, 4Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…
  • Abstract Number: 0751 • ACR Convergence 2021

    Are Current Patient Reported Outcomes Instruments Optimized to Capture the Entire Patient Experience?

    Philip Mease1, Vibeke Strand2, Dan Furst3, Evan Siegel4, Melissa Mcilraith5, Elaine Husni6 and M. Cameron Hay7, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2Stanford University School of Medicine, Portola Valley, CA, 3University of California Los Angeles, Los Angeles, CA, 4Arthritis and Rheumatism Associates, Potomac, MD, 5M.Mc. Consulting, Dallas, TX, 6Cleveland Clinic, Cleveland, OH, 7Miami University (Ohio), Oxford, OH

    Background/Purpose: Psoriatic Arthritis (PsA) affects multiple attributes of patient health; to assess treatment effectiveness a compilation of Patient Reported Outcomes (PRO) have been utilized. While…
  • Abstract Number: 1026 • ACR Convergence 2021

    Factors Impacting Likelihood of Discontinuing Immunosuppression in Adult Dermatomyositis: A Single-Center Study

    Sung Kyung Cho1, Lorinda Chung2 and David Fiorentino3, 1University of Texas Southwestern, Dallas, TX, 2Stanford University, Palo Alto, CA, 3Stanford University, Redwood City, CA

    Background/Purpose: Dermatomyositis (DM) is a chronic idiopathic inflammatory myopathy with variable clinical course, but little is known regarding factors associated with remission of disease. We…
  • Abstract Number: 1410 • ACR Convergence 2021

    Predictors of Relapse in Giant-Cell Arteritis: A Retrospective Single Center Analysis

    Kathleena D'Anna1, David Lim2, Lorena Salto1 and Mehrnaz Hojjati1, 1Loma Linda University Health, Loma Linda, CA, 2Loma Linda University Health, Redlands, CA

    Background/Purpose: Giant Cell Arteritis (GCA) is the most common systemic vasculitis in North America, typically affecting Caucasian female adults over 50 years of age. Flares…
  • Abstract Number: 0441 • ACR Convergence 2021

    A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis

    Pedro Machado1, Richard Barohn2, Michael McDermott3, Thomas Blaetter4, Tom Lloyd5, Aziz Shaibani6, Miriam Freimer7, Anthony Amato8, Emma Ciafaloni3, Sarah Jones9, Tahseen Mozaffar10, Summer Gibson11, Matthew Wicklund12, Todd Levine13, Claus Sundgreen4, Tim Carstensen4, Karen Bonefeld4, Anders Jørgensen4, Karina Phonekeo4, Andrew Heim14, Laura Herbelin14, Michael Hanna15 and Mazen Dimachkie14, 1Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 2University of Missouri - Columbia, Columbia, MO, 3University of Rochester, Rochester, NY, 4Orphazyme A/S, Copenhagen, Denmark, 5Johns Hopkins University, Baltimore, MD, 6Nerve and Musle Center, Houston, TX, 7Ohio State University, Columbus, OH, 8Brigham and Women's Hospital, Boston, MA, 9University of Virginia, Charlottesville, VA, 10University of California Irvine, Irvine, CA, 11University of Utah, Salt Lake City, UT, 12University of Colorado, Denver, CO, 13Phoenix Neurological Associates, Phoenix, AZ, 14University of Kansas Medical Center, Kansas City, KS, 15University College London, London, United Kingdom

    Background/Purpose: Inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy occurring in patients over the age of 45 years. Since immune suppression has…
  • Abstract Number: 0756 • ACR Convergence 2021

    Validation of Two Simple Patient-centered Outcome Measures for Virtual Monitoring of Patients with Idiopathic Inflammatory Myositis

    R Naveen1, Darpan R Thakare2, Vikas Agarwal2, Rohit Aggarwal3 and Latika Gupta1, 1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Changing landscape of patient care from in-person to virtual telemedicine-based consultation in times of a global pandemic has necessitated a wider use of patient-centered…
  • Abstract Number: 1154 • ACR Convergence 2021

    What Do Patients Know About Biosimilars and How Satisfied Are They with the Educational Process? – A Systematic Comparison Between Rheumatologists and Nurse Specialists, Including Effects of Multiswitching

    Sabina Gall, Uta Kiltz, Tanja Kobylinski, Ioana Andreica, Kristina Vaupel, Xenofon Baraliakos and Jürgen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany

    Background/Purpose: The market share of biosimilars (bsDMARDs) is steadily growing, not only in rheumatologic care. Although data on efficacy, efficiency and safety have been generated…
  • Abstract Number: 1451 • ACR Convergence 2021

    Improving Health Outcomes and Social Connectedness Through Virtual Exercise Programs in Community Members with Musculoskeletal Conditions

    Titilayo Ologhobo1, Bertilia Trieu2, Claudia Zurlini1, Bonnie McGrath1, Linda Roberts1, Vilma Briones1, Pamela Sanchez-Villagomez2, Robyn Wiesel1, Sandra Goldsmith1 and Laura Robbins1, 1Hospital for Special Surgery, New York, NY, 2Hospital of Special Surgery, New York

    Background/Purpose: According to the 2020 American Health Ranking System, 26% of adults are physically inactive with a higher prevalence found in adults ages ≥65 years.…
  • Abstract Number: 0450 • ACR Convergence 2021

    Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis

    Mark Hwang1, Minjae Lee2, Lianne Gensler3, Matthew Brown4, Amirali Tahanan5, Mohammad Rahbar6, Theresa Hunter7, Mingyan Shan8, Mariko Ishimori9, John Reveille10, Michael Weisman11 and Thomas Learch12, 1McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, 2UT Southwestern, Dallas, TX, 3Department of Rheumatology, University of California San Francisco, San Francisco, CA, 4King's College London, London, United Kingdom, 5McGovern Medical School, Houston, TX, 6Division of Clinical and Translational Sciences, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, 7Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, 8Eli Lilly and Company, Indianapolis, IN, 9Cedars-Sinai Health System, Los Angeles, CA, 10Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, 11Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, 12Cedars-Sinai, Los Angeles, CA

    Background/Purpose: Little is known about the natural history of spinal disease in Ankylosing Spondylitis (AS). Our objective was to identify distinct patterns of change in…
  • Abstract Number: 0757 • ACR Convergence 2021

    Different Versions of the Patient Global Question in Rheumatoid Arthritis – Does It Really Matter? – Results of a Multi-center Observational Study

    Paul Studenic1, Aliaksandra Baranskaya2, Stanley Cohen3, Nancy Shadick4, Christine Iannaccone5, Maria Dahl Mjaavatten6, Elisabeth Lie7, Tore Kvien8, Josef Smolen9, Daniel Aletaha10 and Helga Radner9, 1Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, 2Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 3Metroplex Clinical Research Center, Dallas, TX, 4Brigham & Women's Hospital, Boston, MA, 5Brigham and Women’s Hospital, Topsfield, MA, 6Diakonhjemmet Hospital, Haslum, Norway, 7Diakonhjemmet Hospital, Oslo, Nepal, 8Diakonhjemmet Hospital, Oslo, Norway, 9Medical University of Vienna, Vienna, Austria, 10Medical University Vienna, Vienna, Austria

    Background/Purpose: The patient global assessment (PGA), typically assessed as 'Considering all of the ways your arthritis has affected you, how do you feel your arthritis…
  • Abstract Number: 1169 • ACR Convergence 2021

    Patient Preferences for Outcome Measures for a Pragmatic Knee Osteoarthritis (OA) Clinical Trial: Results of a Cross-Sectional Patient Survey That Included Racial/Ethnic Minorities

    Jasvinder Singh, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Many effective treatments are available for knee osteoarthritis (OA), however comparative effectiveness research (CER) of various treatments to each other is limited. One of…
  • Abstract Number: 1458 • ACR Convergence 2021

    Sustained Efficacy and Safety of Iberdomide to Week 52 in Patients with Active Systemic Lupus Erythematosus (SLE) in a Phase 2, Randomized, Placebo-Controlled Study

    Joan Merrill1, Victoria Werth2, Richard Furie3, Ronald van Vollenhoven4, Maria Majdan5, Michael Weiswasser6, Shimon Korish6, Zhaohui Liu6, Peter Schafer6 and Nikolay Delev6, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 4Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 5Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland, 6Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: We previously reported 24-wk results of a phase 2b trial of iberdomide, a high-affinity cereblon ligand that promotes proteasomal degradation of Ikaros (IKZF1) and…
  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology